|Institution||Principal Investigator||Other researches|
|CIBER-BBN (coordinator group)||M. Pilar Marco Colás||
|SEPAR||Juan Ruiz Manzano||
|CIBERES||Vicente Ausina Ruiz||
P. aeruginosa is a life-threating and higly virulent pathogen that besides producing many virulence factors is capable of producing biofilms, which protects the microorganism from the host immune system. The lung is the organ associated to the highest mortality rate. Nowadays, pneumonia owed to this pathogen is increasing and its treatment is becoming a challenge due to the appearance of new drug resistances.
P. aeruginosa can be related either to community or hospital-acquired pneumonia, even though it is in the hospital setting where this pathogen has the greatest impact. Bacteriemic P. aeruginosa pneumonia occurs in neutropenic patients after cancer quimiotherapy, and it is also seen occasionally in children and adults with AIDS. The most severe complication of pneumonia is sepsis and septic shock. Bloodstream infection (BSI) is a fulminant disease. Death occurs 3-4 days after signs or symptoms of pulmonary or extrapulmonary infection. It is crucial to start the antimicrobial therapy within the first hours. Moreover, P. aeruginosais known for its capacity of acquiring antibiotic resistance.
The main objective of this project is the development and validation of an impedimetric immunosensor platform that could be used for point of care (PoC) clinical diagnosis to detect P. aeruginosa infections in blood and respiratory samples. The project has a clear translational character, since it uses knowledge and technology already developed to create an in vitro diagnostic device with a clear and well-defined clinical application and with the intention to implement the system in the clinical laboratory after an appropriate validation. The consortium counts from the start of the project with the necessary immunoreagents for the detection of the microorganism, and the impedimetric sensor that will be used as transducer system on the final biosensor device.